Meet our Team
Executive Leadership Team
Transverse Medical is led by a team with decades of extensive multi-disciplinary experience in their respective areas of mastery, coupled with expertise in the healthcare industries of structural heart, cardiovascular, and stroke prevention, creating shareholder value, leading and growing medical technology companies, advancing innovative medical device solutions and game changing technologies, and improving patient outcomes.
-
President & CEO
Co-Founder, Co-Inventor, Board Director
Mr. Goslau is an experienced executive with over 25 years of leadership, commercial sales & marketing, product & business development, and entrepreneurship in the medical device industry. Mr. Goslau leads by example with a hands-on approach working side-by-side with his team, key opinion leaders, and clinical operators, providing a balanced team dynamic and unique culture.
Mr. Goslau is a Co-Founder of Transverse Medical as well as a Co-Inventor on the POINT-GUARD™ Cerebral Embolic Protection Device and serves as a Member of the Board of Directors. As CEO, he leads and oversees all fundraising, operations, clinical planning, regulatory strategy, and product development for the POINT-GUARD™ medical device.
Mr. Goslau has held previous roles in management and at the director level with small to mid-size, and Fortune 500 commercial stage organizations. His career has provided him end-to-end experience in medical device start-up and early-stage corporate strategy and board room governance, planning and executing at all phases of product development and business functions across highly innovative technologies and multiple procedure applications in Structural Heart, Cardiovascular, Stroke, Peripheral, and Endovascular.
Throughout his career, Mr. Goslau has introduced a broad offering of life saving technologies ranging from surgical devices, implantable stents, excimer lasers, electrosurgical devices, and complex vascular grafts as well as co-inventing and developing an innovative medical device solution to prevent strokes during cardiovascular procedures. Atop achieving high performing results and outcomes, Mr. Goslau believes in representing and delivering the best quality products to all customers and their patients.
Mr. Goslau received his Bachelor of Science in business administration with a degree in marketing from the University of Colorado, Leeds School of Business, in Boulder Colorado. Additionally, Mr. Goslau earned a professional executive certificate from UCLA Anderson Graduate School of Business in Strategic Medical Device Marketing.
-
Board Director
Mr. Blowers is Vice Chairman of Northern Trust, a leading provider of wealth management, asset servicing, asset management and banking services for corporations, institutions, families and individuals. Mr. Blowers joined Northern Trust in September of 1982 and has broad leadership experience in both the institutional and private wealth sides of the business.
Mr. Blowers is a member of the Board of Directors and serves as Corporate Secretary for Transverse Medical, Inc. Mr. Blowers joined the Board of Directors in August of 2023 following the closing of the company’s Series B1 financing and brings to the board valuable financial experience, board governance, and fiduciary responsibilities.
Mr. Blowers has enjoyed a successful and privileged career with over 40 years working with Northern Trust and working with both affluent families and large corporations to develop strategies leading towards financial goals. Mr. Blowers has a successful track record of leadership experience in the financial services industry with current responsibilities as one of two Vice Chairmen at the firm where he is focused on senior client relationships, new business development, culture and collaboration, and community engagement.
Mr. Blowers earned a Bachelor of Arts degree in Government from Lawrence University and an MBA with a concentration in Finance from the Kellogg School at Northwestern University.
-
Board Director
Mr. St. Bernard is currently the President & Chief Executive Officer of Alta Biomaterials. Alta Biomaterials is a private equity funded, start-up medical device company focused on developing and commercializing unique polymer technologies designed to address unmet clinical needs in interventional cardiology, interventional oncology, and other emerging medical applications. Prior to joining Alta Biomaterials, Mr. St. Bernard was President & Chief Executive Officer of Tryton Medical, a start-up interventional medicine company that was successfully exited in 2019.
Mr. St. Bernard is an independent member of the Board of Directors for Transverse Medical, Inc. Mr. St. Bernard joined the company in March of 2021 and has served as an Executive Advisor and Board Director. Mr. St. Bernard serves on various company committees and provides executive support, leadership, and board governance.
Mr. St. Bernard has over 30 years of experience in the life sciences field, including pharmaceutical, consumer, medical device, and diagnostics markets. Mr. St. Bernard has broad leadership experience in Cardiology, Ophthalmology, Vascular Surgery, Orthopedics, Radiology, General Surgery, and Plastic Surgery and has held senior executive positions at healthcare leaders such as Johnson & Johnson, Abbott Labs, and GE Healthcare.
Mr. St. Bernard earned a bachelor’s degree in economics and Studio Art from Lafayette College and a master’s degree in business administration from Pepperdine University
-
Board Director
Dr Rahul P. Sharma, MBBS, FRACP is the Director of Structural Interventions at Stanford Healthcare, Associate Director of the Cardiac Catheterization Laboratory and Clinical Associate Professor of Medicine at Stanford University.
Dr. Sharma is an independent member of the Board of Directors and serves as Chair of the Medical Advisory Board for Transverse Medical, Inc. Dr. Sharma joined the Board of Directors in February of 2024 and brings to the board and company his clinical expertise and professionalism coupled with his innovative med-tech entrepreneurship and board level responsibilities.
In addition to Dr. Sharma’s Board Role with Transverse Medical, he is a Co-Founder and Board Member of Synchron, Inc. Synchron is the endovascular brain-computer interface (BC) company developing technology to restore functionality in patients with severe paralysis. The clinical-stage company is developing a neuroprosthesis to restore motor signaling to control digital devices for people with severe motor impairment.
Dr Sharma is an Interventional Cardiologist with specialized clinical and research interests in structural heart disease, particularly transcatheter valve therapy. He has a large volume of expertise in transcatheter valve repair and replacement, left atrial appendage occlusion, PFO/ASD/VSD closure, alcohol septal ablation, intracardiac echocardiography and cerebral embolic protection. Dr Sharma has expertise in the application of artificial intelligence to cardiovascular medicine, serving as the Chief Medical Officer of Egnite. He is a clinical investigator in ongoing national multi-center research studies and clinical trials and has co-authored numerous peer reviewed, scientific articles and book chapters.
Dr Sharma serves as a national and international clinical proctor for transcatheter procedures and is invited regularly to speak at major national and international cardiology meetings.
-
Chief Medical Officer
Dr. Michael J. Reardon is a native Houstonian who attended Baylor College of Medicine where he graduated with honors and as a member of AOA. He did his general surgery residency under Dr. Michael DeBakey and cardiothoracic residency under Dr. Denton Cooley. He joined the staff of the Houston Methodist Hospital in 1985 and ran a private practice until 1993. He then joined the full-time faculty of BCM rising to Professor of Surgery with tenure, Chief of Cardiothoracic Surgery and Director of the thoracic residency program. He subsequently joined the academic group at the HMH as Professor of Cardiothoracic Surgery and Chief of Cardiac Surgery.
Dr. Reardon joined Transverse Medical’s Advisory Board in 2014 and transitioned to Chief Medical Officer in 2020 following the company’s first-in-human experience with the first-generation Point-Guard. Dr. Reardon has been involved with the company through pre-clinical and development activities leading up to in-human clinical trials for the next-generation Point-Guard. His contributions to the development of Point-Guard are coupled with his passion for providing a full-brain protection solution for patients during TAVR and other procedures and where stroke is a risk and embolic protection is of critical importance.
Dr. Reardon has served as elected president of the medical staff for the HMH and received numerous awards including the Overstreet Award and Noon Award. He currently holds the Allison Family Distinguished Chair of Cardiovascular Research and divides his time between building innovative clinical, research and educational programs.
-
Chief Technology Officer
Mr. Blankenship has over 30 years in the medical device industry and has served as a Director, CEO, President, COO and CTO of multiple start-up companies, as well as a product development executive for divisions of Eli Lilly, Pfizer and the Battelle Memorial Institute.
Mr. Blankenship brings to the Transverse Medical team his decades of professional experience within the Medical Device industry. Mr. Blankenship’s history with the development of the Point-Guard and his scientific and technical background in structural heart supports the technical and leadership expertise needed to support the Point-Guard development program.
Mr. Blankenship has led business planning, staffing, funding, design, development, approval, manufacturing, launch and exits via acquisition. He is a medical device development specialist, including conception, design, qualification, production, and FDA and EU product approvals.
Much of Mr. Blankenship’s career has focused on cardiac and cardiovascular products. He has led the design of three implantable heart valves, specialty tools associated with implantation of those heart valves, infrared imaging and RF ablation catheters, visible light angioscopes, and several tools associated with heart surgery in general.
Mr. Blankenship is a graduate of the College of Engineering at Arizona State University, holds numerous US and foreign patents, and is a decorated veteran of the United States Submarine Service.
Medical Advisory Board
The company’s medical advisory board is comprised of physician experts with extensive clinical experience in the field of structural heart and cerebral embolic protection and recognized as key opinion leaders within the industry.
-
Samir Kapadia, MD
Director of Interventional Cardiology & Structural Heart Miller Family Heart & Vascular Institute, Cleveland Clinic Cleveland, Ohio
-
Axel Linke, MD
Professor, Head of Cardiology, Technical University Dresden, Heart Center, Dresden, Sachsen, Germany
-
Srini Iyengar, MD
Director of Structural Heart Boulder Community Health, Boulder Heart at Erie Medical Center, Boulder Heart at Anderson Medical Center, Boulder, Colorado
-
Colin Barker, MD
Director of Interventional & Structural Cardiology Vanderbilt University Medical Center, Division of Cardiovascular Medicine, Associate Professor of Medicine Nashville, Tennessee
Specialty Advisory Board
The company’s specialty advisors are professionals at the executive level within their field of expertise and are passionate believers in Transverse Medical’s Mission for Stroke prevention during Cardiovascular and Structural Heart Procedures.
-
Executive and Board
Stanley “Stan” Lapidus has been providing executive level support and guidance while advising the Company’s CEO and serving as an observer to the Board of Directors since 2018.
Stan founded EXACT Sciences and served as its CEO and Chairman until 2006. Since the commercial introduction of the company’s Cologuard test for non-invasive, early detection of colorectal cancer, EXACT has been the most rapidly growing company in the history of the diagnostics industry.
Prior to EXACT Sciences, Stanley was founder and CEO of Cytyc Corp prior to its acquisition by Hologic for $6.2 billion. He is the principal inventor of Cytyc’s ThinPrep Pap test, which revolutionized screening for cervical cancer and now accounts for approximately 80% of the world market for cervical cancer screening. Stanley was also the founder and CEO of SynapDx and Helicos Biosciences.
-
Clinical Affairs
Thomas Engels has 30 years of clinical research experience, with over 20 years medical devices, the majority being interventional cardiology. Thomas is currently responsible for Clinical and Medical Affairs at LimFlow, a subsidiary of Inari Medical.
Previously, Thomas was Vice President of clinical affairs for Claret Medical, Micell Technologies and CardioKinetix, taking the companies’ novel devices through trials to achieve CE Mark, European post-marketing safety surveillance, Chinese (CFDA) approval and de novo FDA clearance.
Previously, Mr. Engels was director of clinical research for 10 years at Guidant/Abbott Vascular, where he managed its global portfolio of interventional cardiology studies.
Mr. Engels holds a BS from Louisiana State University and MBA degrees from the Columbia Business School and the Haas School of Business at University of California, Berkeley.
-
Regulatory Affairs
Zachary Woodson has worked in the medical device industry for over 26 years with most of that time in the cardiovascular space. He has worked extensively in the quality and regulatory space for both large and small companies.
Mr. Woodson has served as the Vice President of QA/RA for Claret Medical where he helped secure de novo clearance for the first cerebral embolic protection device for use during TAVR. Following Claret Medical, Mr. Woodson continued his successful track record with FDA as Vice President of QA/RA for LimFlow and upon a successful FDA Advisory Committee achieved approval for the LimFlow System, the first device approved for TADV.
-
Technology Advisor
Dr. Abe Zandi has over 30 years’ work experience in technology and product design in DARPA applications, military applications, medical devices, electronics, avionics, optics, aerospace, and green energy harvesting & energy storage. While electro-mechanical design is a primary focus of his work across these markets at both nano and MEMs scales, additional experience includes thermal and mechanical analysis, sensor miniaturization, packaging, electronic and RF assemblies, and procedure and audit approvals within multiple regulatory bodies.
Dr. Zandi is currently the CEO of Bitconcepts engineering that specializes in product design & development where he has contributed to the next generation design of Point-Guard. Dr. Zandi previously held positions as a staff engineer at ITT/Excelis defense, principal engineer at Micromedical Devices Inc., chief engineer at Pacific Antenna Systems and Manager of the R&D group at FMC technologies.
Within these markets, Dr. Zandi applies his extensive simulation expertise in key topics such as: FEA (Finite Element Analysis), CFD (Computational Flow Dynamics (Fluid /Thermal), Shock/Vibration/Impact, Natural Frequency, Static/Dynamic, electromagnetic, and rotor dynamics, test & simulation of multiple complex environments drives, prototyping, integrated and design of sensors and transducers.